Aridis Pharmaceuticals, Inc.
ARDS
$0.0001
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 680.42% | 649.45% | 9.70% | 101.37% | 422.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 680.42% | 649.45% | 9.70% | 101.37% | 422.81% |
| Cost of Revenue | -35.22% | -42.55% | -35.53% | -30.43% | -21.19% |
| Gross Profit | 122.04% | 97.97% | 38.98% | 36.15% | 28.55% |
| SG&A Expenses | -21.94% | -14.25% | -9.47% | -2.04% | 8.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.29% | -38.10% | -31.26% | -25.74% | -16.14% |
| Operating Income | 97.89% | 83.91% | 33.84% | 30.31% | 22.15% |
| Income Before Tax | 96.52% | 79.59% | 31.69% | 28.02% | 16.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 96.52% | 79.59% | 31.69% | 28.02% | 16.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 96.52% | 79.59% | 31.69% | 28.02% | 16.35% |
| EBIT | 97.89% | 83.91% | 33.84% | 30.31% | 22.15% |
| EBITDA | 98.87% | 84.57% | 34.14% | 30.74% | 22.81% |
| EPS Basic | 90.82% | 81.27% | 58.83% | 56.78% | 48.17% |
| Normalized Basic EPS | 91.21% | 82.19% | 57.99% | 54.39% | 45.99% |
| EPS Diluted | 90.51% | 80.95% | 58.70% | 56.66% | 48.05% |
| Normalized Diluted EPS | 90.93% | 82.03% | 57.99% | 54.39% | 45.99% |
| Average Basic Shares Outstanding | 86.30% | 70.34% | 57.23% | 55.24% | 54.37% |
| Average Diluted Shares Outstanding | 87.04% | 71.15% | 57.23% | 55.24% | 54.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |